Evidence map›Paper›PMID 41724874›Full record

Observational studyJournal of gastrointestinal cancer2026

Comprehensive Real-World Outcomes of Multimodal Treatment in Gallbladder Cancer: A Prospective Cohort Study.

Kumar Vineet, Mayank Tripathi, Piyush Kant Shukla, Dhaval Vadodaria, Nitesh Joshi, Mohd Irfan Ansari, Gurupreet Singh Gill, Akash Srivastava, Chandan Kumar

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kumar VineetDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India. likho2vineet@gmail.com.ORCID http://orcid.org/0000-0002-8077-1299
Mayank TripathiDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Piyush Kant ShuklaDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Dhaval VadodariaDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Nitesh JoshiDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Mohd Irfan AnsariDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Gurupreet Singh GillDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Akash SrivastavaDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
Chandan KumarDepartment of Surgical Oncology, MPMMCC & HBCH, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGallbladder cancer is an aggressive malignancy with disproportionately high incidence in North India. Most patients present at advanced stages, limiting curative options. This study aimed to prospectively evaluate outcomes of multimodal treatment-including neoadjuvant chemotherapy, surgery, and palliative chemotherapy-in a high-volume endemic center.

methodsIn this prospective observational cohort, 1,500 newly diagnosed gallbladder cancer patients were enrolled between September 2023 and May 2024. Clinical details, treatment intent, type of therapy, and survival outcomes were systematically recorded. Patients were stratified into three groups: neoadjuvant chemotherapy for borderline resectable disease, upfront curative surgery, and palliative chemotherapy for metastatic disease. Kaplan-Meier analyses were performed for overall survival (OS).

resultsOf 1,500 patients, 1,203 (80.2%) presented with metastatic disease. Among 75 patients who received neoadjuvant chemotherapy, 61.3% progressed and only 12.7% could undergo curative surgery. Overall, 116 patients underwent surgical exploration and 92 received definitive surgery, achieving a 1-year overall survival of 88.5%. Of 768 patients planned for palliative chemotherapy, 294 received ≥ 1 cycle, with a median overall survival of 5 months.

conclusionIn this real-world prospective cohort, surgery remains the only treatment associated with meaningful survival, while neoadjuvant chemotherapy and palliative chemotherapy yielded limited benefit. Early detection and standardized treatment pathways are urgently needed in endemic regions.

Indexed as

Gallbladder NeoplasmsAdultAgedCombined Modality TherapyFemaleHumansIndiaMaleMiddle AgedNeoadjuvant TherapyPalliative CareProspective StudiesSurvival RateTreatment OutcomeChemotherapyGallbladder carcinomaNeoadjuvantPalliativeSurgery

Identifiers

PMID41724874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.